General Statement of Disclosure:
RESEARCH/RESEARCH GRANTS: Amgen Inc.(SIGNIFICANT), Bayer(SIGNIFICANT), NovoNordisk(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Abbott Laboratories(SIGNIFICANT), Agios Pharmaceuticals(SIGNIFICANT), Alexion Pharma(SIGNIFICANT), Angionetics(SIGNIFICANT), Atentiv(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT), Cardiol Therapeutics(SIGNIFICANT), CellResearch(SIGNIFICANT), Cook Regentec(SIGNIFICANT), CSL Behring (SIGNIFICANT), Eidos Therapeutics(SIGNIFICANT), Esperion(SIGNIFICANT), Faraday Pharmaceuticals(SIGNIFICANT), Fortress Biotech(SIGNIFICANT), Heartflow(SIGNIFICANT), Insmed(SIGNIFICANT), Kowa Research(SIGNIFICANT), Lexicon(SIGNIFICANT), Pfizer Inc(SIGNIFICANT), Alnylam(SIGNIFICANT), Array(SIGNIFICANT), Prothena Biosciences(SIGNIFICANT), Regeneron(SIGNIFICANT), Moderna(SIGNIFICANT), Regio Biosciences(SIGNIFICANT), Sanifit(SIGNIFICANT), Sanofi-Aventis(SIGNIFICANT), Stealth BioTherapeutics(SIGNIFICANT), Worldwide Clinical Trials(SIGNIFICANT), PhaseBio(SIGNIFICANT), Janssen Pharmaceuticals, Inc(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Anthos Therapeutics(SIGNIFICANT), Cambrian Biopharma(SIGNIFICANT), Epizon Pharma(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Silence Therapeutics(SIGNIFICANT), Thrombosis Research Institute(SIGNIFICANT), VarmX(SIGNIFICANT), Cleerly(SIGNIFICANT)
